# data[].attributes.body
The first known reference to bleeding disorder appears in the Talmud, describing the practice of exempting boys from circumcision if two previous brothers had died from bleeding after the procedure.

# data[].attributes.body
Dr. John Conrad Otto, a physician in Philadelphia, is the first to recognize hemophilia as a bleeding disorder, noting its prevalance in certain families.

# data[].attributes.body
The term "Hemophilia" is coined by Friedrich Hopff, a student at the University of Zurich, to describe the bleeding condition.

# data[].attributes.body
The discovery of anti-hemophilic globulin (AHG), now known as factor Vlll, by Dr. Patek and Dr. Stetson, is a major milestone in understanding the clotting process.

# data[].attributes.body
Hemophilia B, also known as Christmas Disease, is identified as a separate condition from Hemophilia A, due to its deficiency in factor IX. It is named after Stephen Christmas, the first patient diagnosed with the disorder.

# data[].attributes.body
The development of cryoprecipitate, a plasma fraction rich in factor VIII, revolutionizes treatment for Hemophilia A, allowing for more effective control of bleeding episodes,

# data[].attributes.body
The AIDs epidemic devastates the Hemophilia community, as many patients contract HIV through contaminated blood products.

# data[].attributes.body
Heat treatment of blood products is introduced, significantly reducing the risk of viral contamination (which includes HIV and hepatitis) in clotting factor concentrates.

# data[].attributes.body
Recombinant clotting factors, which are genetically engineered and free human blood, become available, offering a safer treatment option for Hemophilia patients.

# data[].attributes.body
The first gene therapy for Hemophilia is approved for clinical use, offering the potential for long-term control or even a cure for the disorder.